BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1921148)

  • 1. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.
    Warwick GL; Packard CJ; Demant T; Bedford DK; Boulton-Jones JM; Shepherd J
    Kidney Int; 1991 Jul; 40(1):129-38. PubMed ID: 1921148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia.
    Demant T; Gaw A; Watts GF; Durrington P; Buckley B; Imrie CW; Wilson C; Packard CJ; Shepherd J
    J Lipid Res; 1993 Jan; 34(1):147-56. PubMed ID: 8445339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
    Taskinen MR; Packard CJ; Shepherd J
    Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism.
    Packard CJ; Gaw A; Demant T; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):172-87. PubMed ID: 7706942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
    Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
    Gaw A; Packard CJ; Murray EF; Lindsay GM; Griffin BA; Caslake MJ; Vallance BD; Lorimer AR; Shepherd J
    Arterioscler Thromb; 1993 Feb; 13(2):170-89. PubMed ID: 8427854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.
    Demant T; Bedford D; Packard CJ; Shepherd J
    J Clin Invest; 1991 Nov; 88(5):1490-501. PubMed ID: 1939641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
    Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 1997 Feb; 27(2):169-77. PubMed ID: 9061312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
    J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.
    Taskinen MR; Matikainen N; Björnson E; Söderlund S; Inkeri J; Hakkarainen A; Parviainen H; Sihlbom C; Thorsell A; Andersson L; Adiels M; Packard CJ; Borén J
    Diabetologia; 2023 Dec; 66(12):2307-2319. PubMed ID: 37775612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells.
    Krämer-Guth A; Nauck M; Pavenstädt H; Königer M; Wieland H; Schollmeyer P; Wanner C
    J Am Soc Nephrol; 1994 Oct; 5(4):1081-90. PubMed ID: 7849247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model development to describe the heterogeneous kinetics of apolipoprotein B and triglyceride in hypertriglyceridemic subjects.
    Barrett PH; Baker N; Nestel PJ
    J Lipid Res; 1991 May; 32(5):743-62. PubMed ID: 2072038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins.
    Bradley WA; Hwang SL; Karlin JB; Lin AH; Prasad SC; Gotto AM; Gianturco SH
    J Biol Chem; 1984 Dec; 259(23):14728-35. PubMed ID: 6501314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
    Anber V; Millar JS; McConnell M; Shepherd J; Packard CJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2507-14. PubMed ID: 9409221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients.
    Demant T; Mathes C; Gütlich K; Bedynek A; Steinhauer HB; Bosch T; Packard CJ; Warwick GL
    Kidney Int; 1998 Dec; 54(6):2064-80. PubMed ID: 9853272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism.
    Maugeais C; Braschi S; Ouguerram K; Maugeais P; Mahot P; Jacotot B; Darmaun D; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 1997 Jul; 17(7):1369-75. PubMed ID: 9261269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.